InflaRx N.V. Common Stock (IFRX) Stock Price

IFRXStock

$2.23+90.60%52W

Market Cap$328.63M

P/E—

PEG Ratio—

Div yield—

Beta2.62

IFRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)140.93%

Price vs S&P 500 (4W)25.89%

VGM Score31.27

Book Value / Share (Quarterly)$0.59

P/TBV (Annual)1.42x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)107.97%

Gross Margin (TTM)-3693.72%

Net Profit Margin (TTM)-42170.98%

EPS (TTM)$-0.55

10-Day Avg Trading Volume1.10M

EPS Excl Extra (TTM)$-0.55

EPS (Annual)$-0.79

ROI (Annual)-107.39%

Gross Margin (Annual)-24678.79%

Cash / Share (Quarterly)$0.64

Revenue Growth QoQ (YoY)-80.75%

ROA (Last FY)-82.65%

Revenue Growth TTM (YoY)-51.41%

EBITD / Share (TTM)$-0.49

ROE (5Y Avg)-60.62%

Operating Margin (TTM)-35401.52%

Cash Flow / Share (Annual)$-0.57

P/B Ratio6.96x

P/B Ratio (Quarterly)1.52x

Net Income / Employee (Annual)$-814,223

EV / Revenue (TTM)3962.76x

Net Interest Coverage (TTM)-13.98x

ROA (TTM)-51.64%

EPS Incl Extra (Annual)$-0.79

Current Ratio (Annual)4.13x

Quick Ratio (Quarterly)3.88x

3-Month Avg Trading Volume1.64M

52-Week Price Return90.60%

Revenue / Employee (TTM)$1,160

Tangible BV / Share (Quarterly)$0.59

P/S Ratio (Annual)8749.53x

Asset Turnover (Annual)0.00x

52-Week High$3.42

EPS Excl Extra (Annual)$-0.79

CapEx CAGR (5Y)4.20%

Tangible BV CAGR (5Y)-11.74%

26-Week Price Return152.86%

Quick Ratio (Annual)3.88x

13-Week Price Return-6.30%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)4.16x

Enterprise Value$290.72M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-26.92%

Revenue / Employee (Annual)$580

Pretax Margin (Annual)-155545.52%

Cash / Share (Annual)$0.75

3-Month Return Std Dev82.36%

Net Income / Employee (TTM)$-575,789

ROE (Last FY)-109.81%

Net Interest Coverage (Annual)-5.86x

EPS Basic Excl Extra (Annual)$-0.79

Receivables Turnover (TTM)0.02x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-0.55

ROI (TTM)-68.27%

P/S Ratio (TTM)4056.65x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.67

Price vs S&P 500 (52W)72.04%

Year-to-Date Return120.79%

5-Day Price Return8.78%

EPS Normalized (Annual)$-0.79

ROA (5Y Avg)-48.80%

Net Profit Margin (Annual)-155587.38%

Month-to-Date Return31.18%

Cash Flow / Share (TTM)$-0.85

EBITD / Share (Annual)$-0.82

Operating Margin (Annual)-164539.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-59.62%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.55

P/TBV (Quarterly)1.52x

P/B Ratio (Annual)1.41x

Inventory Turnover (TTM)0.71x

Pretax Margin (TTM)-42151.56%

Book Value / Share (Annual)$0.67

Price vs S&P 500 (13W)-8.26%

Beta2.62x

Revenue / Share (TTM)$0.00

ROE (TTM)-69.50%

52-Week Low$0.93

vGradeF

gGradeF

mGradeB

vgmGradeD

IFRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.06	-$0.10	-63.64%(-$0.03)
Q1 2026	May 6, 2026	-$0.17	-$0.09	+45.76%(+$0.08)
Q4 2025	Mar 19, 2026	-$0.17	-$0.17	-2.74%(-$0.00)
Q3 2025	Nov 10, 2025	-$0.14	-$0.21	-46.94%(-$0.07)
Q2 2025	Aug 7, 2025	-$0.24	-$0.24	-3.28%(-$0.01)

IFRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

4.14

4.21

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
IFRXInflaRx N.V. Common Stock	F	F	B	$2.23
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About InflaRx N.V. Common Stock

InflaRx NV is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and inflammatory diseases. The company's lead candidate, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a, a key inflammatory mediator implicated in multiple disease pathways. Clinical data has demonstrated disease-modifying activity and a favorable safety profile. The company is advancing this platform with plans to address multiple therapeutic indications.